

Special Issue

HIV Neurological Disorders: 2nd Edition

Message from the Guest Editor

It became apparent from the Special Issue on [HIV neurological disorders](#) that there are many unresolved challenges. These challenges include, but are not limited to, clinical manifestations, quantitative diagnosis measures, pathological mechanisms and treatment developments. This second Special Issue on HIV neurological disorders can address the different challenges clinicians and researchers are now facing. The mechanism(s) for the production of HIV neurologic disorders remains elusive and complex. In many parts of the world, opportunistic infections still present a continued challenge. Where treatment is available, patients may eventually present with HIV noninfectious comorbidities. Both these situations need to be addressed, but an underlying point in both is the presence of HIV-associated inflammation. The chronic inflammation associated with HIV infection is the main candidate for the production of HIV neurological comorbidity. There is a need for both clinical and basic science research addressing HIV neurologic comorbidity.

Guest Editor

Dr. Frank Denaro

Department of Biology, Morgan State University, Baltimore, MD 21251, USA

Deadline for manuscript submissions

31 May 2026



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/202212

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

[viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.2 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).